A mitochondrial localization signal peptide and its application
By providing a CTSH signal peptide sequence with mitochondrial localization function, especially the CTSH c.31G>A/p.G11R mutation, the problem of lack of mitochondrial localization signal peptide in the prior art is solved, and precise localization and traceability of mitochondria are achieved. New strategies are provided for the treatment and research of mitochondria-related diseases.
Patent Information
- Application Number
- CN202411036884.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-31
AI Technical Summary
There is a lack of signal peptides that can guide the localization of the target protein to mitochondria in the prior art. In particular, CTSH signal peptide mutations have little research on mitochondrial localization function, which has affected the treatment and research of mitochondria-related diseases.
Provide a signal peptide sequence with mitochondrial localization function, including specific amino acid mutations of CTSH signal peptide, such as CTSH c.31G>A/p.G11R, which can be obtained through gene cloning or chemical synthesis and fused with fluorescent proteins to achieve mitochondria. positioning and traceability.
Accurate localization and traceability of mitochondria, providing new strategies for the treatment and research of mitochondria-related diseases, which can be used to prepare vaccines for the treatment of genetic diseases, malignant tumors, hematological diseases, viruses, parasites, bacterial infections and drug.
Smart Images

Figure CN118599819B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine and relates to a mitochondrial localization signal peptide and an application thereof. Background Art
[0002] Organelles constitute the basic structure of cells, enabling eukaryotic cells to work and operate normally. Organelles are a type of functionally independent subcellular structure that is separated from other parts of the cell by biological membranes. Organelles can be roughly divided into three categories according to the number of membrane layers they have: double-layer membrane organelles mainly include mitochondria and chloroplasts, etc.; single-layer membrane organelles mainly include endoplasmic reticulum, Golgi bodies and lysosomes, etc.; membraneless organelles mainly include ribosomes and centrosomes, etc.
[0003] Mitochondria are two-layer membrane-enclosed organelles that exist in most cells. They are the main place for cells to carry out aerobic respiration and are also called energy factories. The diameter of mitochondria is about 0.5 to 1.0 microns. Most eukaryotic cells have mitochondria to a greater or lesser extent, but the mitochondria they have vary in size, number, and appearance. For example, there are 1,000 to 2,000 mitochondria in liver cells. Mitochondria have their own genetic material and genetic system, but their genome size is limited. They are semi-autonomous organelles, and the mitochondrial genome is maternally inherited. According to statistics, there are 1,136 mitochondrial-localized proteins in the human body. Most of these proteins are encoded by nuclear DNA, then synthesized on ribosomes, and then transported to mitochondria; the remaining proteins are encoded by the mitochondrial genetic material itself. In addition to providing energy for cells, mitochondria are also involved in processes such as cell differentiation, cell information transmission, and cell apoptosis, and have the ability to regulate cell growth and cell cycle. Abnormal mitochondrial function is closely related to many diseases, such as neurological diseases, cardiovascular and cerebrovascular diseases, maternally inherited Leigh syndrome, mitochondrial myopathy, Leer hereditary optic neuropathy and other mitochondrial diseases; in addition, mitochondria also maintain close interactions with other organelles. Once mitochondria are damaged, the interaction between organelles will be affected. Studies have also found that changes in mitochondrial function can promote tumor metastasis. Mitochondria have a very sophisticated and complex protein transport system, including sorting and positioning signal peptides and transport complexes in mitochondrial proteins. Under the joint action of these positioning sequences and transport complexes, many mitochondrial proteins are accurately transported to different parts of mitochondria through various sorting pathways. Therefore, by studying these positioning sequences, mitochondria can be better traced.
[0004] The study of protein transport and subcellular localization has great application value, because the function of protein is usually closely related to its subcellular localization. For example, the secretory protein of pathogens is often an important virulence factor and is closely related to its pathogenicity. In addition, signal peptides are also widely used in drug targeted delivery and disease treatment. For example, nuclear localization signals can be used to transfer therapeutic genes to the cell nucleus, thereby performing cell-directed gene therapy for diseases. Since mitochondria are related to a variety of diseases, especially some diseases caused by mitochondrial gene mutations, mitochondrial localization signal peptides can target therapeutic genes to mitochondria and perform mitochondrial-directed gene therapy, providing a good prospect for gene therapy. The study of mitochondrial localization signal peptides can not only reveal the biological functions and mechanisms of mitochondrial localization proteins, but also provide technical support for the development of specific mitochondrial-targeted biotechnology drugs.
[0005] Lysosomal cathepsin H (Cathepsin H, CTSH) is a type of tissue protease that is mainly distributed in the cytoplasm and lysosomes. Lysosomal proteins also have a sophisticated and complex protein sorting system. The correct CTSH protein signal peptide sequence can ensure that CTSH is eventually transported to the lysosome for processing and eventually forms a protease with enzymatic activity. The inventor's team previously conducted whole exome sequencing on Alzheimer's disease (AD) patients in my country and found that CTSH The gene is a new AD susceptibility gene, and CTSH Increased gene expression was significantly associated with the risk of AD. CTSH The non-synonymous variant rs2289702 (CTSH c.31G>A / p.G11R) in the gene coding region can interfere with the transcription factor CTSH Gene binding, followed by downregulation CTSH Gene expression reduces the risk of AD and exerts a protective effect against AD.
[0006] After searching, no reports were found in the prior art that the polypeptides after CTSH signal peptide mutation have the ability to guide the target protein to localize to mitochondria. Summary of the invention
[0007] In view of the above technical problems, the present invention aims to provide a signal peptide sequence with mitochondrial localization function, which can guide the target protein to localize to mitochondria.
[0008] The first aspect of the present invention provides a signal peptide for localizing mitochondria, and the signal peptide includes one or more of the following: (a) a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOs. 6, 14, 18, and 20; (b) a polypeptide comprising the amino acid sequence shown in (a) after one or more of the substitutions, deletions, and insertions of one or more amino acids.
[0009] The present invention also protects a fusion protein, which comprises the above-mentioned mitochondrial localization signal peptide and target protein.
[0010] Furthermore, the target protein is a fluorescent protein.
[0011] Furthermore, the mitochondrial localization signal peptide is located at the N-terminus of the target protein.
[0012] The present invention also protects a recombinant expression vector, which contains a gene sequence encoding the above-mentioned mitochondrial localization signal peptide, and the DNA sequence encoding the mitochondrial localization signal peptide is selected from any one of SEQ ID NO.7, 15, 19, and 21.
[0013] The present invention also protects a host cell, wherein the host cell contains the recombinant expression vector as described above.
[0014] The present invention also protects the use of mitochondrial localization signal peptides, fusion proteins, recombinant expression vectors or host cells, including the following aspects:
[0015] 1) Prepare products that locate mitochondria or indicate the specific location or morphology of mitochondria;
[0016] 2) Prepare products that localize or import target proteins into mitochondria;
[0017] 3) Preparation of products that overexpress the target protein in mitochondria;
[0018] 4) Preparation of drugs for the treatment of mitochondrial-related diseases; preparation of vaccines for mitochondrial-related diseases;
[0019] 5) Prepare products for studying the interaction between target protein and mitochondria.
[0020] Furthermore, the mitochondria-related diseases include genetic diseases, malignant tumors, blood diseases, viruses, parasites, and bacterial infections.
[0021] Compared with the prior art, the present invention has the following beneficial technical effects:
[0022] The present invention first discovered that when the 11th amino acid of the mouse or human CTSH signal peptide mutates from glycine to arginine (CTSH c.31G>A / p.G11R), it has the function of guiding the target protein to localize to the mitochondria. The truncated form of the first 15 amino acids of the mouse CTSH or human CTSHp.G11R mutant signal peptide also has the function of guiding the target protein to the mitochondria. The mitochondrial localization signal peptide of the present invention can be obtained by gene cloning or direct chemical synthesis, and then fused with a fluorescent protein, which can achieve mitochondrial tracing, indicate mitochondrial morphology and position, and provide a new strategy for mitochondrial tracing. The mitochondrial localization signal peptide provided by the present invention and a suitable target protein form a fusion protein to obtain vaccines and drugs for treating genetic diseases, malignant tumors, blood diseases, viruses, parasites, bacterial infections and other diseases, and achieve efficient directional drug delivery, which is of great value to the fields of biotechnology and medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Plasmid plvx-puro-CTSH G11R -HA profile;
[0024] Figure 2 Overexpression of wild-type CTSH in 293T cells WT -HA and CTSH G11R -HA mutant protein band changes. Note: KO means knockout cells; KO-OE-Lentivirus-CTSH means exogenous gene expression in knockout cells by lentivirus infection;
[0025] Figure 3 The result diagram of CTSH p.G11R is that CTSH can be directed to mitochondria, where Figure A is CTSH WT -HA immunofluorescence results; Figure B is the co-localization analysis results of Figure A; Figure C is CTSH G11R -HA immunofluorescence results; Figure D is the co-localization analysis result of Figure C. HA is CTSH, Mito-Red mitochondrial probe. Note: The red fluorescent signal is the Mito-Red mitochondrial probe; the green fluorescent signal is the HA protein signal of the CTSH-HA vector; the yellow fluorescent signal indicates that the red fluorescence and the green fluorescence are co-localized;
[0026] Figure 4 For CTSH G11R -HA protein enrichment results in mitochondrial components;
[0027] Figure 5 Figure 1 is a diagram of the CTSH protein structure analysis, wherein Figure A is a schematic diagram of the CTSH protein amino acid sequence; Figure B is a diagram of the key active amino acid sites predicted for the CTSH protein;
[0028] Figure 6 The figure shows the sequencing results of the fluorescent expression vectors fused with CTSH wild-type and mutant signal peptides (WT-GFP and G11R-GFP). WT-GFP and G11R-GFP are GFP with CTSH wild-type signal peptide (WT) and CTSH mutant signal peptide (G11R), respectively.
[0029] Figure 7 This is a comparison of the results of WT-GFP and G11R-GFP localization in mitochondria in immunofluorescence experiments, where Figure A is the immunofluorescence result of WT-GFP; Figure B is the co-localization analysis result of Figure A; Figure C is the immunofluorescence result of G11R-GFP; Figure D is the co-localization analysis result of Figure C; WT-GFP and G11R-GFP are GFP with CTSH wild-type signal peptide (WT) and CTSH mutant signal peptide (G11R), respectively; Mito-Red mitochondrial probe;
[0030] Figure 8 For CTSH G11R -signal-peptide-GFP protein enrichment diagram in mitochondrial components;
[0031] Fig. 9 A comparison diagram of the amino acid sequence of CTSH signal peptide protein among multiple species;
[0032] Fig.10 This is the sequencing result of mCtsh p.G11R signal peptide GFP plasmid;
[0033] Fig.11 For immunofluorescence experiments mCtsh WT -GFP and mCtsh G11R -GFP localization results of mitochondria; Figure A is the immunofluorescence experiment mCtsh WT -GFP localization results of mitochondria, Figure B is an enlarged view of the fusion image in Figure A; C is the immunofluorescence experiment mCtsh WT -GFP and mCtsh G11R -Results of GFP localization in mitochondria, Figure D is an enlarged view of the fusion image in Figure C;
[0034] Fig.12 Truncated 15AA-CTSH for immunofluorescence experiments WT -GFP and truncated 15AA-CTSH G11R - Comparison of mitochondrial localization of GFP, where Figure A is the truncated 15AA-CTSH WT -GFP immunofluorescence localization of mitochondria results, Figure B is an enlarged view of the fusion image in Figure A; Figure C is a truncated 15AA-CTSH G11R-GFP immunofluorescence localization results of mitochondria, Figure D is an enlarged view of the fusion image in Figure C. DETAILED DESCRIPTION
[0035] In order to better explain the present invention, the following is described in conjunction with specific experimental schemes and experimental results. The experimental methods described below are all conventional methods unless otherwise specified. The experimental materials used in the following description are all conventional biochemical reagents, which can be purchased from corresponding biological reagent companies unless otherwise specified.
[0036] Cell line: U251-APP cells (U251 cells were purchased from the cell bank of Kunming Institute of Zoology, Chinese Academy of Sciences). The construction method of U251-APP was derived from [1]
[0037] Mainly used biochemical reagents:
[0038] Phosphate buffered saline (PBS) (Servicebio, G0002-15), phosphate buffered saline (Servicebio, G4202-500ML), fetal bovine serum (FBS) (Gibco-BRL, 10099-141), double antibody (penicillin and streptomycin) (Gibco-BRL, 10378016), 0.25% Trypsin-EDTA trypsin (Gibco, 1806021), puromycin (Solarbio, P8230), Opti-MEM reduced serum medium (Gibco, 11058021), DMEM (Dulbecco's modified eagle medium) (Gibco, 11965092), RPMI1640 medium (Gibco, 11875093), genomic DNA extraction kit (Axygen, 26817KC1), endotoxin-free plasmid mini-preparation kit (TIANGEN, DP118-02), general DNA product purification kit (TIANGEN, DP204-03), agarose gel DNA recovery kit (enhanced) (TIANGEN, DP219-02), DH5α Chemically Competent Cell (Qingke Biotechnology, TSC-C14), P cloning sticky end kit (Qingke Biotechnology, TSV-007S), P cloning blunt end kit (Qingke Biotechnology, TSV-007B), 1.1×T3 Super PCR Mix (Qingke Biotechnology, TSE030), Gold Mix (Qingke Biotechnology, TSE101), Lipofectamine 3000 transfection kit (ThermoFisher Scientific, L3000015), KOD-Plus-Neo high-fidelity enzyme (TOYOBO, KOD-401), FastDigest DpnI (ThermoFisherScientific, FD1704), agarose powder (Shenggong, 111860), LB medium (Sigma, L3522), FastDigestBamHI (ThermoFisher Scientific, FD0054), FastDigest XhoI (ThermoFisherScientific, FD0694), anti-fluorescence quenching sealing solution (Biyuntian, P0126), immunostaining permeabilization solution (Triton X-100 (Biyuntian, P0096), DAPI (Biyuntian, C1002), polybrene (Sigma, TR-1003), paraformaldehyde (Paraformaldehyde) (Sigma, 158127). .
[0039] Mainly used expression vectors:
[0040] The construction method of pTango-zeo-C1ORF141-CEGFP was derived from [2] ,mito-Red(PT3633-5),plvx-puro-CTSH WT -HA with plvx-puro (PPL, PT4002-5), plvx-puro--CTSH G11R -HA (in the form of plvx-puro-CTSH WT -HA plasmid as a template, self-constructed), CTSH WT -signal-peptide-GFP and -CTSH G11R -signal-peptide-GFP (self-constructed using pTango-zeo-C1ORF141-CEGFP plasmid as template), mCtsh WT -signal-peptide-GFP and mCtsh G11R -signal-peptide-GFP (self-constructed using pTango-zeo-C1ORF141-CEGFP plasmid as template)
[0041] 1. Luo R, Su LY, Li G, et al. Activation of PPARA-mediated autophagyreduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy 2020; 16: 52-69.
[0042] 2. Bi R, Li Y, Xu M, et al. Direct evidence of CRISPR-Cas9-mediated mitochondrial genome editing. The Innovation 2022; 3: 100329.
[0043] Example 1 Preparation method and function verification of mitochondrial localization signal peptide
[0044] 1.1. Construction of CTSH p.G11R point mutation expression vector
[0045] The plasmid plvx-puro-CTSH purchased from PPL WT -HA was used as a template to obtain the plasmid plvx-puro-CTSH with mutation by PCR amplification. G11R -HA, plasmid map as Figure 1 The specific experimental steps are as follows:
[0046] plvx-puro-CTSH WT -HA was used as a template, and the mutation site was introduced by point mutation primers. The human CTSH p.G11R point mutation primers are:
[0047] CTSH-31-F:TCTGCGCCAGGGCCT
[0048] CTSH-31-R: GGCCCTGGCGCAGAG, the primer sequence is shown in SEQ ID NO. 1-2,
[0049] Then, the plasmid was amplified by PCR using the plasmid as a template. After amplification, the PCR amplification product was digested with FastDigest DpnI to remove the original plasmid template in the PCR product (because the template plasmid is derived from conventional Escherichia coli and is modified by dam methylation). DpnI can recognize methylation and remove the template (the methylated GATC sequence is the DpnI recognition sequence, and the GATC sequence is widely present in various plasmids, so the plasmid template can be removed by recognizing this sequence, and the plasmid with the mutation site obtained by PCR amplification will not be digested by DpnI because there is no methylation, so it can be successfully transformed in the transformation experiment, so the mutant plasmid can be obtained). After DpnI digestion, the digestion product was purified and recovered by a common DNA product purification and recovery kit. The DH5α competent cells were mixed with the purified and recovered PCR product, and then the transformation experiment was carried out (volume ratio 100:10). The bacterial solution after incubation in the biochemical incubator was smeared on the LB plate with ampicillin resistance. The smeared LB plate was inverted and placed in a 37 ℃ biochemical incubator for overnight incubation. The next morning, a single clone colony was picked and expanded for culture, plasmid DNA was extracted and sequenced to verify whether it contained the target mutation site, and the successfully constructed mutant plasmid was saved for later use. The specific experimental method is as follows:
[0050] Table 1 PCR point mutation system
[0051]
[0052] Table 2 PCR point mutation program
[0053]
[0054] Table 3 DpnI restriction enzyme system and method
[0055]
[0056] Prepare the DpnI digestion system in a 1.5 mL centrifuge tube according to the sample loading order in the above table, then place the 1.5 mL centrifuge tube at 37°C for 1 hour for digestion, and then perform a normal DNA product purification and recovery experiment.
[0057] (4) The steps for purification and recovery of common DNA products are as follows:
[0058] 1) Equilibrate the adsorption column CB2. Add 500 μL of equilibration solution BL to the adsorption column CB2 to be used later (the adsorption column needs to be placed in the collection tube), centrifuge at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and then put the adsorption column CB2 back into the collection tube for standby use; add 5 times the volume of binding solution PB to the PCR reaction solution or enzyme digestion reaction solution (i.e., the PCR product after DpnI digestion), and mix with a pipette (no need to remove paraffin oil or mineral oil). If the PCR reaction system is 50 μL, add 250 μL of binding solution PB. Transfer the resulting solution to an adsorption column CB2 after equilibrium (the adsorption column is placed in the collection tube), place it at room temperature for 2 min, centrifuge it at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and place the adsorption column CB2 back in the collection tube. Add 600 μL of rinse solution PW to the adsorption column CB2 (add anhydrous ethanol according to the instructions of the kit or the label on the reagent bottle before use, mix well before use), place it at room temperature for 5 min, centrifuge it at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and place the adsorption column CB2 back in the collection tube. Repeat the previous step; place the adsorption column CB2 back in the collection tube, centrifuge it at 12000 rpm (~13400 × g) for 2 min, and discard the waste liquid in the collection tube. Place it at room temperature for 10 min and dry it thoroughly. Put the adsorption column CB2 back into a new clean 1.5 mL centrifuge tube, add 30 μL of elution buffer EB to the center of the adsorption column CB2 membrane, and leave it at room temperature for 2 min. Centrifuge at 12000 rpm (~13400 × g) for 2 min to collect the purified and recovered DNA solution. In order to improve the efficiency of DNA purification and recovery, the centrifuged solution can be re-suspended and added to the center of the adsorption column CB2 membrane, left at room temperature for another 2 min, centrifuged at 12000 rpm (~13400 × g) for 2 min, and the centrifuged DNA solution can be collected again, which is the purified and recovered DNA solution. The concentration and purity of the purified and recovered DNA solution were detected by agarose gel electrophoresis and ultra-micro spectrophotometer NanoDrop 2000.
[0059] (5) The transformation experiment steps are as follows:
[0060] Take 1 tube of DH5α competent cells (volume 100 µL) and place it on ice to thaw for about 3 min. Add 10 µL of the target DNA solution (DNA solution purified and recovered in the previous step), gently mix the cell suspension with a pipette, and place the mixed cell suspension on ice for 30 min. After standing on ice for 30 min, place the cell suspension in a 42 ℃ water bath for heat shock for 45 s. After the heat shock, quickly place the cell suspension in an ice bath and let it stand for 2 min. In the clean bench, add 700 µL of sterile liquid culture medium (such as LB culture medium) without antibiotics to the centrifuge tube containing the cell suspension, mix gently with a pipette, and place the competent cell suspension horizontally in a biochemical incubator at 37 ℃ and 200 rpm for 60 min. According to the experimental needs, take different volumes (100 µL in this experiment) of the recovery solution and evenly apply it to the LB solid culture medium (plate) containing ampicillin antibiotics, and then place the plate upside down in a 37 ℃ incubator for overnight culture. The next morning, pick the monoclonal colonies on the plate in the clean bench and expand the culture in LB liquid medium with ampicillin (final concentration of ampicillin is 50 μg / mL), extract the plasmid DNA and sequence to verify whether it contains the target mutation site, and save the plasmid with successful mutation for later use.
[0061] (6) The experimental steps for extracting plasmid DNA using the endotoxin-free plasmid mini-extraction kit are as follows:
[0062] Column equilibration step: Add 500 µL of equilibration solution BL to the adsorption column CP4 (the adsorption column is placed in the collection tube), centrifuge at 12000rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and then put the adsorption column CP4 back into the collection tube for use. Take 15 mL of overnight cultured bacterial solution into a 2 mL centrifuge tube, centrifuge at 12000 rpm (~13400 × g) for 1 min at room temperature, and discard the supernatant medium. Add 500 µL of solution P1 to the 2 mL centrifuge tube with bacterial pellet (before using solution P1, please add RNaseA included in the kit to solution P1), and use a pipette or vortex shaker to thoroughly suspend the bacterial cell pellet. This step requires that the bacterial cell pellet be thoroughly suspended until there are no obvious clumps when observed with the naked eye. Add 500 µL of solution P2 to the centrifuge tube, gently invert the centrifuge tube up and down 8 times to allow the solution in the centrifuge tube to fully lyse the bacterial cell clumps. At this time, the bacterial solution should become clear and viscous after mixing the tube. Add 500 µL of solution P4 to the centrifuge tube, mix immediately and invert the centrifuge tube 8 times to mix the solution thoroughly. At this time, a white flocculent precipitate should appear, and then the centrifuge tube should be left at room temperature for 10 minutes. Then centrifuge at 12000 rpm (~13400 × g) for 10 minutes. After centrifugation, a large amount of precipitate should appear at the bottom of the centrifuge tube. Solution P4 needs to be mixed immediately after adding to avoid local reaction and local precipitation. If there are still small white particles in the supernatant after centrifugation, you can centrifuge again and take the supernatant. Transfer the supernatant collected in the previous step to the filter column CS (the filter column is placed in the collection tube, and the maximum volume of the filter column is 800 µL) in batches, centrifuge at 12000 rpm (~13400 × g) for 2 minutes, and collect the filtrate in a new clean 2 mL centrifuge tube. Add 0.3 times the volume of isopropanol to the collected filtrate, mix well, and transfer to the equilibrated adsorption column CP4 in batches (the maximum volume of the adsorption column is 800 µL, and the adsorption column CP4 is placed in the collection tube). Centrifuge at room temperature at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, put the adsorption column CP4 back into the collection tube, add the liquid mixed in the previous step again, repeat the centrifugation operation, discard the filtrate, and put the adsorption column CP4 back into the collection tube. Until the transfer of the mixed liquid in the previous step is completed. Add 500 µL of deproteinized solution PD to the adsorption column CP4, centrifuge at room temperature at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and put the adsorption column CP4 back into the collection tube. Add 600 µL of rinse solution PW to the adsorption column CP4 (add anhydrous ethanol according to the instructions of the kit or the label on the reagent bottle before use, mix well before use), leave at room temperature for 5 min, centrifuge at 12000 rpm (~13400 × g) for 1 min, discard the waste liquid in the collection tube, and put the adsorption column CB2 back into the collection tube.Repeat the above steps. Put the adsorption column CP4 back into the collection tube, centrifuge at 12000 rpm (~13400 × g) for 2 min, discard the waste liquid in the collection tube, place the adsorption column CP4 in a new clean centrifuge tube, leave it at room temperature for 10 min, and dry it thoroughly; add 100 µL of elution buffer TB to the middle part of the adsorption membrane of the adsorption column CP4 in mid-air and leave it at room temperature for 2 min. Centrifuge at 12000 rpm (~13400 × g) for 2 min to collect the plasmid solution into the centrifuge tube. In order to improve the recovery efficiency of plasmid DNA, the centrifuged solution can be re-suspended and added to the center of the adsorption column CP4 membrane, leave it at room temperature for another 2 min, centrifuge at 12000 rpm (~13400 × g) for 2 min, and collect the centrifuged plasmid DNA solution again. The obtained plasmid DNA can be frozen for future use, and on the other hand, the concentration and purity of the extracted plasmid DNA can be detected by agarose gel electrophoresis and UV spectrophotometer.
[0063] 1.2. Build with CTSH WT -signal-peptide-GFP and CTSH G11R -signal-peptide-GFP signal peptide fluorescent plasmid
[0064] The plasmid plvx-puro-CTSH purchased from PPL WT -HA and the successfully constructed plvx-puro-CTSH G11R -HA was used as a template to design PCR primers for cloning the CTSH plasmid signal peptide region and human CTSH signal peptide cloning primers:
[0065] MTS-CTSH-BamHI-F:CGCGGATCCATGTGGGCCACGCTGCC
[0066] MTS-CTSH-XhoI-R: CCGCTCGAGGGCACCGCAGACGGGGA, the primer sequence is shown in SEQ ID NO. 3-4.
[0067] At the same time, add BamHI restriction sequence and protection base sequence (protection restriction site) to the 5' end of the upstream primer; add XhoI restriction sequence and protection base sequence to the 5' end of the downstream primer, and clone CTSH WT Wild type and CTSH G11R The signal peptide sequence of the mutant, the human CTSH WT Wild type and CTSH G11R The amino acid sequence of the mutant polypeptide is shown in SEQ ID NO. 5-6, and the human CTSH WTWild type and CTSH G11R The DNA sequence of the signal peptide of the mutant is shown in SEQ ID NO.7-8, and then the template plasmid is removed with DpnI enzyme, and the product after DpnI digestion is purified and recovered with a PCR product purification and recovery kit, and the concentration of the recovered product is determined (the specific operation is the same as above). The purified PCR product is then double-digested with BamHI and XhoI enzymes, and the double-digestion system is as follows:
[0068] Table 4 Double enzyme digestion working solution-PCR product
[0069]
[0070] Prepare the double enzyme digestion mixture according to the above system and place it in a water bath at 37 ℃ for 1 hour. At the same time, use the pTango-zeo-C1ORF141-CEGFP plasmid as a template and use BamHI and XhoI enzymes to perform double enzyme digestion at the same time. The double enzyme digestion system is as follows:
[0071] Table 5 Double enzyme digestion working solution-plasmid
[0072]
[0073] After the double enzyme digestion experiment is completed, the double enzyme digestion product is purified and recovered using a common purification and recovery kit. Then, the clone with CTSH WT Wild type and CTSH G11R The signal peptide fragment of the mutant was connected to pTango-zeo-C1ORF141-CEGFP, and the connection system was as follows:
[0074] Table 6 T4 DNA ligase working solution
[0075]
[0076] Prepare T4 DNA ligase ligation system according to the above table, mix gently and place in 22 ℃ PCR instrument for 1 hour. After the ligation reaction, start the transformation experiment, and then extract plasmid DNA and sequence to verify whether the plasmid is successfully constructed. The specific experimental operation is the same as above. WT -signal-peptide-GFP and CTSH G11R -signal-peptide-GFP signal peptide fluorescent plasmid such as Figure 6 shown.
[0077] 1.3. Express the successfully constructed plasmid in cells by liposome transfection
[0078] The main method is to use liposome-mediated exogenous DNA expression, and use the Lipofectamine 3000 transfection kit to complete the plasmid DNA exogenous expression experiment. The following is a description of the cell 6-well plate system. The specific method is as follows:
[0079] 1) One day in advance, seed cells into 6-well plates (2 × 10 5 / well), the cell density needs to be calculated in advance. The transfection experiment started 24 hours after inoculation (cell density is about 80% - 90%).
[0080] 2) Prepare the transfection system according to the following table
[0081] Table 7 Transfection working solution formula
[0082]
[0083] This system is mainly suitable for 6-well plate system. If the transfection system is a 12-well plate or a 24-well plate, the amount of each reagent in the system can be reduced in equal proportion.
[0084] 3) After tube A and tube B are prepared, mix the two tubes together, gently pipette to mix, and let stand for 15 minutes; replace the cell culture medium in the 6-well plate with Opti-MEM medium (500 μL / well for 6-well plate); after tube A and tube B are mixed and let stand for 15 minutes, the mixed solution is evenly added to the corresponding 6-well plates, and then the solution in the well plate is gently shaken and placed in a 37 ℃ incubator with 5% CO2 and 95% humidity for 4-6 hours; after incubating in Opti-MEM for 4-6 hours, switch to normal culture medium to culture cells.
[0085] 1.4 Immunofluorescence experiment
[0086] 1) Cell treatment and cell fixation: The target cells were seeded into chamber slides in advance at a cell density of 5 × 10 4 Cells were fixed at 4% 4% PFA at 37°C for 15 min or overnight at 4°C.
[0087] 2) Cell membrane perforation and blocking: discard the 4% PFA fixative and wash with PBS 3 times at room temperature, 5 min / time. Then add 500 μL TritonX-100 reagent to perforate the cell membrane and let it stand at room temperature for 10 min. Blocking: discard the TritonX-100 reagent, wash with PBS once at room temperature, 5 min / time, add 500 μL 5% BSA blocking solution for blocking, and block at room temperature for 30 min.
[0088] 3) Incubation of primary antibody and secondary antibody: discard the blocking solution, wash with PBS 3 times at room temperature, 5 min / time, then add primary antibody (such as HA antibody and CTSH antibody, the ratio of primary antibody should be determined according to the antibody manual), and incubate overnight at 4 ℃. Incubation of secondary antibody: recover the primary antibody incubation solution, wash with PBS 3 times at room temperature, 5 min / time, then add the secondary fluorescent antibody of the corresponding species, and incubate at room temperature for 1 hour.
[0089] 4) Nuclear staining, sealing, and photographing: discard the secondary antibody incubation liquid, wash with PBS 3 times at room temperature, 5 min / time, then add DAPI reagent (staining concentration is 10 μg / mL) to stain the nucleus at room temperature for 10 min;) Sealing: discard the DAPI solution, wash with PBS 3 times at room temperature, 5 min / time. Then add anti-fluorescence quencher to the cell surface for sealing. Use laser confocal or other fluorescence high-resolution microscopes for observation and photography.
[0090] 1.5. Detection of target vector protein expression
[0091] Western Blot technology is mainly used to detect whether the exogenous expression plasmid is expressed normally. The specific operation is as follows:
[0092] 1) Protein extraction and total protein concentration determination: Use WB / IP cell lysis buffer to lyse the single cell aggregates collected after expansion culture and extract total cell protein. First, add 18 μL PBS to the 96-well plate, then add 2 μL of the sample to be tested, and then add 200 μL / well of the mixture of solution A and solution B (volume ratio 50:1) in the BCA kit. After the reagents are added, place the 96-well plate in a biochemical incubator at 37 ℃ for 30 min, and then use an enzyme reader to determine the protein concentration. Calculate the volume and solution required for each group of samples when the standard loading amount is 20 μg for protein phenotype. The denatured samples can be used directly for subsequent experiments or placed in a -80 ℃ refrigerator for later use (please refer to 2.2 for details).
[0093] 2) Denature the protein samples: Based on the measured concentration, the total volume of each sample is 20 μL. Then take 20 μg of protein and 4 μL of 5 × SDS-PAGE protein loading buffer, add PBS to 20 μL, mix well, centrifuge appropriately, and then heat denature at 95 °C for 5 min, and then immediately place on ice for 3 min.
[0094] 3) Electrophoresis and transfer: Add the denatured protein in the previous step to the SDS-PAGE gel wells, run at 80 V for 40 min, and then run at 120 V for 90 min. Dissolve the SDS-PAGE transfer powder purchased from Servicebio in water. Each bag of SDS-PAGE transfer powder can be prepared with 1 L transfer solution (800 mL water plus 200 mL methanol), mix well and set aside. Then cut a PVDF membrane of similar size to the PAGE gel, place the PVDF membrane in the methanol solution for 30 sec to activate the PVDF membrane, and then place it in the transfer solution for use. Then soak the filter paper and sponge (similar in size to the PAGE gel) in the transfer solution, and complete the transfer by "sandwich" and "wet transfer". "Sandwich": Place the "sandwich" into the transfer apparatus soaked with transfer solution in the order of black-side transfer apparatus - sponge - filter paper - protein gel - PVDF membrane - filter paper - sponge - white-side transfer apparatus (the transfer process will release heat, so ice water is needed to maintain a certain low temperature). The "wet transfer" should not exceed 2.5 hours, and the transfer conditions are 100V, 200 mA (single transfer apparatus).
[0095] 4) Blocking, incubating primary antibodies and incubating secondary antibodies: After the transfer, remove the PVDF membrane from the "sandwich" and transfer it to a blocking solution prepared with 1 × TBST and 5% skim milk powder solution, and incubate it on a horizontal shaker at room temperature for two hours. After the blocking is completed, wash the PVDF membrane with 1 × TBST 3 times, 5 min / time, at room temperature on a horizontal shaker to remove all the residual blocking solution on the PVDF membrane. After the membrane washing is completed, according to the experimental requirements, plan the molecular weight of the target protein in advance, and then cut the PVDF membrane according to the size of the target protein antibody, and then pour the antibodies into the box containing the cut PVDF membrane, and incubate it in a 4 ℃ refrigerator overnight. The next day, the primary antibodies in the 4 ℃ refrigerator were recovered into the original tubes, and the PVDF membrane was washed 3 times, 5 min / time, on a horizontal shaker at room temperature to remove all the residual primary antibodies on the PVDF membrane. Then, prepare the secondary antibody dilution solution according to the species of the primary antibody and incubate the cells on a horizontal shaker at room temperature for 1 hour.
[0096] 5) Washing and development: After incubating the secondary antibody at room temperature, discard the secondary antibody and wash the PVDF membrane 3 times with 1 × TBST on a horizontal shaker at room temperature for 5 min / time to remove the residual secondary antibody on the PVDF membrane and avoid interference with subsequent development. Mix the chemiluminescent substrate A solution and the chemiluminescent substrate B solution according to the equal volume (volume ratio 1:1) preparation method to prepare the developing working solution. Then put the PVDF membrane in a ziplock bag, add the developing working solution to the PVDF membrane, and use the Bio-Rad fluorescent image analyzer for exposure and development.
[0097] 1.6. Principle and method of mitochondrial protease protection experiment
[0098] Since mitochondria are organelles with a double-layer membrane structure, the extracted mitochondrial proteins can be treated with proteases. If a protein is located in the outer membrane or outside of the mitochondria, it will be digested and degraded by proteases; conversely, if a protein is located inside the mitochondria, the protein will be protected by the mitochondrial membrane and resist degradation by proteases. Based on this principle, the inventors used a concentration of 15 μg / mL Proteinase K to treat the crudely extracted mitochondrial protein suspension, reacted on ice for 30 min, immediately added PMSF (1 x) to terminate the reaction, and then performed a protein denaturation experiment, and finally verified the distribution of the target protein through a WB experiment.
[0099] Experimental results:
[0100] (1) Expression of CTSH p.G11R mutation resulted in the appearance of a new protein band in CTSH. CTSH 293T cells (KO) overexpressing CTSH WT In the wild type, the CTSH antibody band is consistent with the wild type cell 293T band (28 kDa), indicating that the present invention overexpresses CTSH WT The plasmid can correctly express the CTSH target protein, while the HA antibody recognizes the CTSH precursor (41 kDa), indicating that CTSH WT The plasmid construction was successful. G11R When mutants were detected, CTSH G11R The mutant did not form the 28 kDa mature CTSH, but instead formed a new truncated form ( Figure 2 ), suggesting CTSH G11R The mutation may mediate some new protein processing mode, leading to the emergence of new truncations.
[0101] (2) The CTSH p.G11R mutation changes the subcellular localization of CTSH and translocates the CTSH protein to the mitochondria. CTSHOverexpression of CTSH in U251-APP cells WT -HA and CTSH G11R -HA, by tracing the HA tag. CTSH was found WT -HA wild type showed a cytoplasmic distribution; while CTSH G11R -HA showed a distribution similar to dot-like aggregates, combined with Mito-Red probe (fused mitochondrial gene COX8A The red fluorescent expression plasmid of the signal peptide was used as a positive control for mitochondrial tracing), suggesting that the CTSH p.11G>R mutation can translocate CTSH to mitochondria ( Figure 3 ).
[0102] In addition, CTSH was further demonstrated by extracting mitochondrial proteins. G11R The mutant has mitochondrial localization function. First, the extracted protein components were divided into two groups: crude mitochondrial components and other components except mitochondria. Known mitochondrial proteins, such as MFN2 and COXIV, are enriched in mitochondrial components, while cytoplasmic proteins such as TUBULIN and GAPDH are enriched in other components. For CTSH, we detected wild-type CTSH in the crude mitochondrial components. WT -HA, but it was mainly enriched in other components, indicating that wild-type CTSH WT -HA is mainly distributed in the cytoplasm, and a small amount is distributed in the mitochondria ( Figure 4 ), this result is consistent with the previous immunofluorescence results, both of which can prove that CTSH WT -HA wild type is mainly distributed in the cytoplasm. Interestingly, the results showed that CTSH G11R The -HA mutant was significantly enriched in the mitochondrial fraction, which further confirmed that CTSH G11R The mutant translocated to mitochondria ( Figure 4 The inventors further determined that CTSH G11R -Whether HA can enter the mitochondria or just stay on the outer membrane. Mitochondria are double-membrane organelles. When treated with proteinase K, proteins located in the mitochondria will be protected by the mitochondrial membrane and will not be degraded by proteinase K. Based on this principle, crude mitochondria were treated with different concentrations of proteinase K and then mitochondrial proteins were extracted. The results showed that mitochondrial outer membrane proteins such as MFN2 could be detected in the mitochondrial components ( Figure 4 ), but could not be detected in the mitochondrial fraction treated with proteinase K ( Figure 4 ); In contrast, the mitochondrial inner membrane protein COXIV can still be detected in the mitochondrial fractions treated with proteinase K ( Figure 4 CTSH is enriched in mitochondrial components.G11R -HA was no longer detectable after proteinase K treatment, indicating mutant CTSH G11R -HA is concentrated in mitochondria and functions in the outer membrane of mitochondria.
[0103] (3) The CTSH p.G11R mutation is located in the signal peptide region of the CTSH protein.
[0104] In order to further study the structural domain of the CTSH protein on which the amino acid encoded by the CTSH p.G11R mutation is located, the CTSH protein structure was analyzed using the AlphaFold Protein Structure Database protein structure prediction website (https: / / alphafold.ebi.ac.uk / ) and the NCBI database and literature reports. The human CTSH protein signal peptide consists of 22 amino acids. The amino acid encoded by the CTSH p.G11R mutation site is located at the 11th amino acid in the signal peptide region, resulting in a mutation from glycine to arginine (p.G11R) ( Figure 5 ). The amino acid sequences of the human CTSH protein signal peptide and mutant peptide are shown in SEQ ID NOs. 5-6, and the DNA sequences encoding them are shown in SEQ ID NOs. 7-8, respectively.
[0105] (4) The CTSH p.G11R mutant signal peptide can direct GFP to mitochondria.
[0106] To further explore CTSH G11R Whether the mutation-mediated CTSH translocation to mitochondria is directly mediated by the signal peptide, WT The signal peptide sequence of the wild type is similar to that of CTSHG11RCTSH G11R The signal peptide sequence of the mutant was cloned upstream of the GFP fluorescent protein (the signal peptide was fused to the GFP sequence and located at the N-terminus of the GFP sequence. Figure 6 ).
[0107] The successfully constructed wild-type CTSH guide peptide GFP (WT-GFP) fluorescent protein expression plasmid and mutant CTSH guide peptide GFP (G11R-GFP) fluorescent protein expression plasmid were overexpressed in U251-APP cells with CTSH gene knocked out, and it was found that the GFP fluorescent protein fused with WT wild-type signal peptide (WT-GFP) was diffusely distributed throughout the cell ( Figure 5 ), while the GFP fluorescent protein fused with the G11R mutant signal peptide (G11R-GFP) co-localized with the mitochondrial fluorescent probe Mito-Red ( Figure 7 ), proving that the wild-type CTSH protein signal peptide does not have mitochondrial localization function, while CTSHG11R The mutant CTSH protein signal peptide has the function of mitochondrial localization and can localize the GFP fluorescent protein to the mitochondria. In addition, using the same biochemical method to verify, it was found that the GFP protein of the G11R mutant signal peptide was enriched in the mitochondrial component, further verifying that the CTSH protein signal peptide with the CTSHp.G11R mutation has the function of mitochondrial localization ( Figure 8 ).
[0108] It can be seen that the mitochondrial fluorescent localization polypeptide of the present invention can show the co-localization phenomenon of mitochondrial probes and has no toxic side effects on cells, and can be used to overexpress genes or serve as a mitochondrial indicator protein in basic research related to mitochondria.
[0109] (5) The sequence similarity of the CTSH p.G11R mutant signal peptide is high among different species.
[0110] By comparing the amino acid composition of CTSH signal peptides in multiple species, it was found that the CTSH signal peptide region (the first 22 amino acids) is relatively conservative, especially the first 15 amino acids. In addition, the position of the CTSH p.G11R mutation is more conservative ( Fig. 9 ). Therefore, it is inferred that the signal peptide of the CTSH protein mutation (CTSH p.G11R) in different species also has the function of mitochondrial localization.
[0111] By PCR cloning related methods (the same method as in Example 1.2), a GFP vector with a mouse CTSH wild-type signal peptide was obtained. The mouse CTSH wild-type signal peptide cloning primer sequence is as follows:
[0112] Mouse-MTS-CTSH-BamHI-F:cgcggatccatgtgggctgcgctgcc
[0113] Mouse-MTS-CTSH-XhoI-R: ccgctcgagggcggtggccccagtactc, the primer series is shown in SEQ ID NOs. 9-10.
[0114] After obtaining the GFP plasmid with the mouse CTSH wild-type signal peptide, the mouse CTSH p.G11R mutant signal peptide GFP plasmid was obtained according to the method for constructing a point mutation plasmid (the method is the same as in Example 1.1). The primer sequences for constructing the mouse CTSH p.G11R mutant signal peptide GFP plasmid are as follows:
[0115] Mouse-G11R-F: TGTGCGCTAGGGCCTGG
[0116] Mouse-G11R-R: CCAGGCCCTAGCGCACA, the primer sequence is shown in SEQ ID NO. 11-12.
[0117] The amino acid sequences of the mouse CTSH wild-type signal peptide and the mouse CTSH p.G11R mutant signal peptide are shown in SEQ ID NOs. 13-14, and the DNA sequences encoding them are shown in SEQ ID NOs. 15-16. The GFP plasmids carrying the mouse CTSH p.G11R mutant signal peptide (mCtsh G11R -signal-peptide and GFP plasmid without mouse CTSH p.G11R mutant signal peptide (mCtsh WT -signal-peptide, the sequencing results of mouse CTSH signal peptide-related plasmids were all correct ( Fig.10 ). According to the above method, they were transfected into mouse N2A cells respectively.
[0118] The results showed that the mouse CTSH p.G11R mutant signal peptide could also localize GFP to mitochondria, that is, the mouse CTSH p.G11R mutant signal peptide had mitochondrial localization function ( Fig.11 ).
[0119] (6) The 1-15 truncated mCtsh p.G11R mutant signal peptide also has mitochondrial localization function.
[0120] When analyzing the species conservation of the CTSH protein signal peptide, the inventors found that the first 15 amino acids of the CTSH protein signal peptide were relatively conservative. By in vitro chemical synthesis, the truncated sequences of human and mouse CTSH p.G11R mutations were obtained respectively (Qingke Company, Order No. KM0052572). The sequences of the first 15 amino acids of the human CTSH signal peptide, the first 15 amino acids of the human CTSH p.G11R mutant signal peptide, the first 15 amino acids of the mouse CTSH signal peptide, and the first 15 amino acids of the mouse CTSH p.G11R mutant signal peptide are shown in SEQ ID NOs. 17-20, respectively, and the DNA sequences encoding them are shown in SEQ ID NOs. 21-24, respectively. When this 15-amino acid sequence was fused with the GFP fluorescent protein, it was also found that the truncated sequence with the mCTSH p.G11R mutation still had the mitochondrial localization function ( Fig.12 ). Fig.12 The results showed that both mouse CTSH and human CTSH p.G11R mutant signal peptide truncated with the first 15 amino acids could guide GFP protein to mitochondria.
Claims
1. A mitochondrial localization signal peptide, characterized in that: The signal peptide includes one or more of the following: a polypeptide consisting of an amino acid sequence shown in any one of SEQ ID NOs. 6, 14, 18, and 20.
2. A fusion protein comprising the mitochondrial localization signal peptide according to claim 1 and a target protein.
3. The fusion protein according to claim 2, characterized in that: The target protein is a fluorescent protein.
4. The fusion protein according to claim 2, characterized in that: The mitochondrial localization signal peptide is located at the N-terminus of the target protein.
5. A recombinant expression vector, comprising a gene sequence encoding the mitochondrial localization signal peptide according to claim 1, wherein the DNA sequence encoding the mitochondrial localization signal peptide is selected from any one of SEQ ID NO. 7, 15, 19, and 21. A host cell comprising the recombinant expression vector according to claim 5 .
7. A use of the mitochondrial localization signal peptide according to claim 1, the fusion protein according to claim 2, the recombinant expression vector according to claim 5 or the host cell according to claim 6, characterized in that: Including the following aspects: 1) Prepare products that locate mitochondria or indicate the specific location or morphology of mitochondria; 2) Prepare products that localize or import target proteins into mitochondria; 3) Preparation of products that overexpress the target protein in mitochondria; 4) Prepare products for studying the interaction between target proteins and mitochondria.
